Leerink Partnrs Reduces Earnings Estimates for InflaRx

InflaRx (NASDAQ:IFRX) – Stock analysts at Leerink Partnrs lowered their FY2024 earnings estimates for InflaRx in a research report issued on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($1.02) per share for the year, down from their prior forecast of ($0.99). The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for InflaRx’s Q4 2024 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS and FY2026 earnings at ($0.93) EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of InflaRx in a research note on Monday, November 11th.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $1.95 on Thursday. The business’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $1.52. The firm has a market capitalization of $114.82 million, a PE ratio of -1.81 and a beta of 1.57. InflaRx has a 1-year low of $1.16 and a 1-year high of $2.44.

Institutional Investors Weigh In On InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC increased its position in InflaRx (NASDAQ:IFRX) by 2.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the period. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.